About Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc., founded in 2016, is developing innovative therapies for eye and skin conditions using novel drug delivery approaches and repurposed compounds. The company's lead programs target common but inadequately treated ophthalmic conditions. TARS stock price reflects investor interest in the company's focused development strategy and potential for addressing large unmet medical needs.

Led by CEO Bobak Azamian, MD, PhD, Tarsus has advanced its lead program through clinical trials while building additional pipeline opportunities in ophthalmology and dermatology. The management team combines medical expertise with drug development experience in specialty therapeutic areas. Leadership's strategic focus on addressing common conditions with limited treatment options has been important for building commercial potential and influencing TARS stock price trajectory.

Tarsus operates by developing therapies for prevalent eye conditions including blepharitis and Meibomian gland dysfunction, which affect millions of patients worldwide but have limited effective treatments. The company's approach combines established drugs with novel delivery methods to improve efficacy and patient outcomes. With large addressable markets in common eye conditions, potential for broad patient adoption and commercial success, and Tarsus' clinical progress demonstrating therapeutic potential, TARS offers investors exposure to ophthalmic therapeutics with significant market opportunity and potential for meaningful patient impact in conditions affecting quality of life.